Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People Briefs

This article was originally published in The Gray Sheet

Executive Summary

Sunshine Heart solidifies CEO appointment; Cook Endoscopy names new president; and more personnel updates from around the industry.

You may also be interested in...

Shuren In The Lion’s Den: Device Center Chief Defends LDT Plan At Clinical Lab Meeting, Fields Wide Array Of Questions

FDA device center Director Jeff Shuren explained and defended fine points of FDA’s proposed laboratory-developed test framework before some of his sharpest critics: members of the American Clinical Laboratory Association, who face an entirely new regulatory scheme once the LDT proposal is finalized.

People Briefs: Medtronic, Hologic, Cook Group, AxoGen, Rivanna

Medtronic exec VP and president, restorative therapies group; Hologic announces board changes; Cook Group names new president; AxoGen chief marketing officer resigns; Rivanna Medical appoints clinical advisor.

Research In Brief

Cook hemostasis spray: Early results of a safety study conducted in China show firm's endoscopic spray helps patients with peptic ulcer bleeds achieve hemostasis and stops re-bleeding, Cook reports April 7. Featuring a proprietary powder that can be sprayed directly onto a bleeding ulcer through the channel of an endoscope, the product may offer an alternative to devices like heating probes and clips in treating gastrointestinal (GI) bleeding, Barry Slowey, global business unit leader for Cook's endoscopy unit, said in an interview. Depending on the results of the 20-patient safety trial, which will be presented at the 2010 Digestive Disease Week conference in May, Cook will decide whether to move forward with a larger clinical study of the spray for GI bleeding by mid-year. About four to five million patients are treated annually for GI bleeds, representing a market of $160 million, Slowey noted


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts